Sun Pharma launches Riomet ER oral suspension in the USA

Indian drugmaker Sun Pharmaceutical Industries (BSE: 524715) has launched Riomet ER (metformin) in the USA as an adjunct to diet and exercise to improve glycemic control in patients 10 years of age and older with type 2 diabetes mellitus.

Riomet ER was approved by the US Food and Drug Administration on August 29, 2019. Riomet ER dosed once daily, is the first and only FDA-approved liquid formulation of extended-release metformin. It can be prepped and poured, thereby eliminating the need to crush medication. The availability of a liquid formulation addresses the needs of patients with type 2 diabetes mellitus, including residents in long-term care facilities, who often have issues swallowing solid medications. Riomet ER offers dosing flexibility and an acceptable taste.

“As the fourth Sun Pharma product designed to address the needs of the 40% of US adults who cannot or will not swallow solid medications, Riomet ER reflects our continued commitment to providing alternative formulations to underserved patient populations,” said Abhay Gandhi, chief executive, North America, Sun Pharma. “Our sprinkle and liquid formulation products treat common, chronic diseases – type 2 diabetes, hypertension, elevated cholesterol, pain and depression – where adherence issues are common and can be life-threatening,” he added.